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While many groups demonstrated new muscle tissue formation after muscle precursor cell (MPC) injection, the capacity of these
cells to heal muscle damage, for example, sphincter in stress urinary incontinence, in long-term is still limited. Therefore, the ﬁrst
goal of our project was to optimize the functional regenerative potential of hMPC by genetic modiﬁcation to overexpress human
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (hPGC-1α), key regulator of exercise-mediated adaptation.
Moreover, we aimed at establishing a feasible methodology for noninvasive PET visualization of implanted cells and their
microenvironment in muscle crush injury model. PGC-1α-bioengineered muscles showed enhanced marker expression for
myogenesis (α-actinin, MyHC, and Desmin), vascularization (VEGF), neuronal (ACHE), and mitochondrial (COXIV) activity.
Consistently, use of hPGC-1α_hMPCs produced signiﬁcantly increased contractile force one to three weeks postinjury. PET
imaging showed distinct diﬀerences in radiotracer signals ([18F]Fallypride and [11C]Raclopride (both targeting dopamine 2
receptors (D2R)) and [64Cu]NODAGA-RGD (targeting neovascularization)) between GFP_hMPCs and hD2R_hPGC-1α_hMPCs.
After muscle harvesting, inﬂammation levels were in parallel to radiotracer uptake amount, with signiﬁcantly lower uptake in
hPGC-1α overexpressing samples. In summary, we facilitated early functional muscle tissue regeneration, introducing a novel
approach to improve skeletal muscle regeneration. Besides successful tracking of hMPCs in muscle crush injuries, we showed
that in high-inﬂammation areas, the speciﬁcity of radioligands might be signiﬁcantly reduced, addressing a possible bottleneck
of neovascularization PET imaging.
1. Introduction
A promising treatment option for various muscle-related
diseases, for example, stress urinary incontinence, is the use
of autologous stem cells for restoration of damaged muscle
ﬁbers, for example, in the urinary sphincter. Muscle precur-
sor cells (MPCs) represent the cell population that has been
shown to be indispensable for skeletal muscle regeneration
[1]. Due to their potential to diﬀerentiate into myoblasts
and the ability to later form new contractile myoﬁbers, MPCs
are being investigated for muscle tissue engineering and
reconstruction in the treatment of a variety of muscle dis-
eases [2–4]. Still, two main concerns about their successful
and safe clinical application are unsolved: the volumetric loss
of the bioengineered tissues over time and the missing tools
for noninvasive imaging of the fate of the implanted cells.
A major shortcoming of the implantation of hMPCs
is their decreased growth capacity in the aged population
[5–7]. This challenge for autologous cell therapy may be
addressed by exercise and/or therapeutic regulation of gene
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expression, which enhances the ability of MPCs to restore
muscle ﬁbers. Reduced physical activity is linked to many
chronic diseases. The understanding of the molecular
mechanisms behind the regeneration of impaired muscle
tissue (e.g., damaged urinary sphincter) is vital for the
development of proper treatment strategies. One key player
in the regulation of exercise-mediated adaptations and of
neuromuscular activity of skeletal muscles is the transcrip-
tional coactivator peroxisome proliferator-activated receptor
(PPAR) γ coactivator 1α (PGC-1α) [8, 9]. Its expression in
muscle tissue is proportional to the amount of exercise and
has been shown to counteract atrophy [10]. Atrophy is a
major limitation hindering skeletal muscle tissue bioengi-
neering. PGC-1α plays an essential role in the regulation
of cellular diﬀerentiation, development, and metabolism
(carbohydrate, lipids, and protein) of higher organisms
[10, 11]. PGC-1α is further regulating the mitochondrial
biogenesis and is adapting the oxidative state in muscles. In
skeletal muscle, PGC-1α is abundant and particularly
enriched in slow-twitch, oxidative muscle ﬁbers, containing
a large number of mitochondria. Importantly, oxidative mus-
cle ﬁbers are the dominant type in the external urinary
sphincter [12]. It has been shown that increased levels of
PGC-1α can promote a shift in the ﬁber composition toward
high-endurance muscle ﬁbers [13, 14]. Furthermore, this
muscle phenotype is characterized by pronounced tissue vas-
cularization [15], increased myoglobin levels, and enhanced
import of glucose, lipids, and lactate [16]. In addition,
PGC-1α tightly links muscle and nerve by regulating neuro-
muscular junction genes and by promoting clustering of ace-
tylcholine receptors (ACHR) at the motor endplate [17]. It
has been proposed that PGC-1α controls muscle plasticity
and suppresses a broad inﬂammatory response [18]. There
is further evidence suggesting that oxidative metabolism
and inﬂammation counteract each other in muscle tissue,
outlining the central function of PGC-1 α in muscle recovery.
Therefore, emphasizing the use of PGC-1α alteration opens
up for novel muscle tissue engineering approaches [19] and
possible clinical applications [20] in urology and beyond.
Besides the volumetric loss of bioengineered tissues,
another shortcoming in the ﬁeld is the missing tools for non-
invasive imaging of this cell therapy. Research towards the
noninvasive imaging of autologous stem cell therapies is of
high importance as both repeated biopsy and access to many
organs are often not clinically feasible. Several modalities are
being investigated for their applicability in cell tracking and
cell metabolism read-outs [21]. While MRI has lower sensi-
tivity compared to radionuclide-based tools and biolumines-
cence has poor spatial resolution, PET/CT is a system with
both high sensitivity and resolution [21]. Additionally,
although imaging reporter genes are available for ﬂuores-
cence, bioluminescence, and MRI, only radionuclide-based
reporter genes are currently investigated for use in patients
[22–27]. In our previous work, we developed a feasible
method for in vivo tracking of subcutaneously injected
hMPCs using [18F]Fallypride, a well-established dopamine
2 receptor (hD2R) PET ligand [28]. After the successful gen-
eration of adenoviruses for the overexpression of a signalling-
deﬁcient hD2R in hMPCs, we were able to establish an ex situ
model for imaging of bioengineered muscle tissue [28]. This
encouraged us to concentrate our further investigations
towards the applicability of these methods in an in situ mus-
cle crush model studying skeletal muscle regeneration,
thereby coming closer to a model for studying urinary
sphincter muscle restoration.
In this regard, we aimed at examining the inﬂuence of
genetically modiﬁed hPGC-1α overexpressing hMPCs,
injected in a skeletal muscle after crush injury, speciﬁcally
investigating the eﬀect on tissue regeneration and muscle
contractility. We expected to improve the cellular therapy
for clinical implementation in stress urinary incontinence
patients in the future, restoring the functionality of the exter-
nal urinary sphincter (predominantly oxidative type ﬁbers
[12]). Moreover, we used a method for noninvasive PET
tracking by ectopic hD2R expression in the implanted cells
[28] and visualization of the neovascularization in the regen-
erating muscle tissue. We hypothesize that by enhancing the
hPGC-1α expression in hMPCs, we can improve the regener-
ation capacity and contractility of the injured muscles.
2. Materials and Methods
2.1. Isolation and Expansion of hMPCs.Human muscle biop-
sies from theM. rectus abdominis were collected upon ethical
approval and with informed consent of 6 hospitalized
patients undergoing abdominal surgery under general anes-
thesia. The patients were selected according to strict inclu-
sion and exclusion criteria, assuring the optimal quality of
the muscle biopsy (e.g., no muscular dystrophy, hormonal
therapy, and chronic infectious diseases). The samples were
processed according to established protocols [29]. Brieﬂy,
each muscle biopsy was ﬁrst minced and digested with colla-
genase type I 0.2% (w/v) (Sigma) and dispase 0.4% (w/v)
(Gibco). The enzymatic reaction was terminated with
medium containing 10% FBS. Individual ﬁbers were then lib-
erated by rigorous pipetting and ﬁltered through a strainer
with a pore size of 100μm. After centrifugation, the pellet
was resuspended in culture medium and the muscle ﬁbers
transferred into 35mm dishes coated with collagen type I
(1mg/ml) (BD). The culture medium consisted of DMEM/
F12, 1% penicillin/streptomycin, 18% FBS, 10 ng/ml hEGF
(Sigma), 1 ng/ml hbFGF (Sigma), 10μg/ml human insulin
(Sigma), and 0.4μg/ml dexamethasone (Sigma) [29]. After
24 h, a ﬁbroblast reduction step was performed by replating
the cells. The cultured hMPCs were characterized as pub-
lished before [14, 29].
2.2. Adenoviral Design and Transduction. The AdEasy Sys-
tem was used as a tool for recombinant adenovirus genera-
tion. For the ﬁrst construct, N-terminal HA-tagged human
PGC-1α was cloned into an adenoviral vector that codes for
CMV promoter-driven green ﬂuorescent protein (GFP).
The expression of hPGC-1α was also under the control of a
CMV promoter, thereby ensuring its robust, constitutive
expression [14]. For the second construct, phenylalanine
411 of the human D2R was mutated into alanine (F411A)
to obtain a signalling-deﬁcient human dopamine D2 receptor
that still binds ligands in a normal manner but will not
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activate intracellular signalling upon ligand binding [28, 30].
As a control for viral infection, a GFP adenovirus was used.
The viral titer was increased through additional ampliﬁcation
steps and quantiﬁed by ﬂuorescent microscopy. The optimal
multiplicity of infection (MOI) was measured by serial titra-
tions of the viral vectors on hMPCs and simultaneous deter-
mination of ﬂuorescent cells, cell toxicity, and cell viability
and proliferation. Detailed descriptions of the performed
assays were published before [14, 28]. Finally, the transduced
hMPCs were expanded for 2 days after infection and were
injected at the injured site in nude mice.
2.3. Animal Experimentation. All animal experiments were
approved by and performed according to the local commis-
sion for animal experiments. A total of 49 female 8-week-
old, nude mice (Charles River, Germany) received hind limb
lateral incisions on both sides (from the inferior tibioﬁbular
joint up to the knee joint) under general anesthesia (3%
isoﬂurane) and aseptic conditions, according to a modiﬁed
published protocol [31]. Brieﬂy, a coronal plane beneath
the tibialis anterior (TA) was opened, separating the muscle
from the tibia. The lower jaw of nonserrated forceps was
gently inserted below the TA. Crush injury was performed
by closing the forceps to its ﬁrst stage for 3 seconds. The
forceps was gently removed, the hMPC collagen suspension
was injected, and the wound was closed. Each injection
contained 6× 106 transduced hMPCs, which were gently
mixed with 100μl collagen type I carrier (ﬁnal concentra-
tion: 2mg/ml) (BD) prior to injection. A volume of 30μl
of the collagen cell suspension could be injected without
leakage. The muscles were harvested 9± 1 days (early),
18± 3 days (midterm), or 31± 3 days (late) after injection.
The deviation in time periods was mandatory due to a com-
plex regimen in repetitive PET imaging with diﬀerent tracers
in the same animal.
2.4. Radiosynthesis of [11C]Raclopride. The radiosynthesis of
[11C]Raclopride was successfully accomplished using an
established procedure in our lab. Brieﬂy, cyclotron-
produced [11C]CO2 gas was reacted with H2 using Ni catalyst
to aﬀord [11C]CH4, which was passed through an I2 column
to yield [11C]CH3I. [
11C]CH3I was then reacted with the des-
methyl precursor for 5min at 90°C. After HPLC puriﬁcation
and SPE extraction, [11C]Raclopride was obtained in 99%
radiochemical purity with a maximal speciﬁc activity of
239GBq/μmol. A total of 1.09–1.72GBq of [11C]Raclopride
was obtained in an injectable solution of 5% EtOH in
0.15M PBS. PET scans with [11C]Raclopride were acquired
from 0 to 60min p.i., and time frames were averaged for
data analysis.
2.5. Radiosynthesis of [64Cu]NODAGA-RGD. In order to
image neovascularization, we used [64Cu]NODAGA-RGD
to target the growth factor integrin αvβIII. Ammonium ascor-
bate (0.5M, pH5.5) was added to [64Cu]CuCl2 (50μl in
0.05N HCl) obtained commercially or produced at Paul
Scherrer Institute (PSI), followed by an addition of 40μl of
NODAGA peptide (NODAGAc(RGDfk), 1mM in H2O).
Labeling was carried out at 95°C for 15 minutes. According
to analytical HPLC, 90% of 64Cu activity was chelated and
only 10% [64Cu]CuCl2 remained unreacted. To bind this
remaining fraction, 5μl DTPA (1 g/15ml) was added. The
resulting [64Cu]DTPA complex is known to be easily
excreted through the renal pathway. Animals were injected
with 5–10MBq [64Cu]NODAGA-RGD in the tail vein and
were imaged 17–22 h p.i.
2.6. Standardized Uptake Value (SUV). SUV is a semiquanti-
tative parameter representing radioactivity concentration in
tissue. It is mathematically deﬁned as the ratio of tissue radio-
activity concentration to injected radioactivity per kilogram
body weight at a certain point during the PET studies.
2.7. Immunohistological Assessment. The harvested TA
muscles were embedded in cryopreservative (OCT embed-
ding medium, Cell Path) immediately after isolation. Cryo-
stat sections were prepared (10μm) and further processed.
For immunohistological analysis, the tissues were ﬁxed (4%
PFA, 10min), permeabilized (0.5% TritonX-100, 20min),
blocked for 30min (5% BSA+0.1% TritonX-100 in PBS),
and ﬁnally stained with anti-sarcomeric α-actinin (1 : 200,
Sigma) and F4/80 (1 : 100, Abcam) over night at 4°C.
After washing with PBS, the tissues were incubated with
Cy3 anti-mouse IgG secondary antibody (1 : 1000, Sigma)
and DAPI (1 : 100, Sigma) for 1 h at room temperature,
washed again, and ﬁnally mounted (Dako). Images were
acquired with a Leica-Imager Type DM6000B at exposures
normalized to unstained controls (secondary antibody and
DAPI only).
2.8. Macrophage Staining Analysis. A computer-assisted
approach was used to quantify macrophage (F4/80) immu-
nolabelling. Longitudinal TA muscle sections were imaged
using the Leica-Imager Type DM6000B, and the images
used for analysis were captured from the crushed (central)
region of the harvested muscles. For evaluation of the signal
(% area), 5–20 high-power ﬁelds (HPF, 20x) were analyzed
by ImageJ per time point and per group.
2.9. Real-Time PCR. For the analysis of PGC-1α
downstream-regulated genes and skeletal contractile muscle
genes in the regenerating tissue by RTPCR, the middle of
the crushed region of each harvested TA muscle was excised,
pulverized in liquid nitrogen, and suspended in RNA lysis
buﬀer. Total RNA was isolated using the SV Total RNA Iso-
lation System kit (Promega) according to the manufacturer’s
protocol, including a DNase digestion. RNA was reverse
transcribed with random primers (high-capacity cDNA
reverse transcription, Life Technologies). Predesigned
primers for human PPARGC-1 (Hs01016719_m1), D2DR
(dopamine 2 receptor, Hs00241436_m1), VEGF (vascular
endothelial growth factor, Hs00900055_m1), MyH1 (myosin
heavy chain 1, Hs00428600_m1), MyH2 (myosin heavy
chain 2, Hs00430042_m1), Desmin (Hs00157258_m1), α-
actinin (Hs00998100_m1), COXIV (cytochrome c oxidase
subunit 4,Hs00971639_m1), vWf (Mm00550375_m1),
TNF-α (tumor necrosis factor alpha, Mm00443258_m1),
and ACHE (acetyl choline esterase, Hs00241307_m1) were
purchased from Life Technologies. 18S rRNA (4319413E)
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was used to normalize cDNA concentrations. For quantiﬁca-
tion, the expression of each gene was normalized to the 18S
expression in the corresponding sample.
2.10. Organ Bath (Myography). The muscles were isolated at
diﬀerent time points after the lesion, and the posttraumatic
functional recovery was quantitatively assessed by organ
bath. After harvesting, the tissues were kept under tension
with constant oxygenation (95% O2 and 5% CO2) in Krebs
solution at 25°C. TA muscles were fastened with vicryl into
the myograph chambers (DMT, Denmark) and allowed to
equilibrate under 15 mN (1.5 g) for 20min, adjusting the ten-
sion periodically and replacing Krebs solution every 5min.
The samples were stimulated by electrical ﬁeld stimulation
(EFS) (80V, 80Hz), and 3 measurements per sample were
considered for the analysis. Native TA muscle (TA nat) was
used as control, and the contraction force was set to 100%.
Forces of injured muscles were calculated relatively as the
percentage of maximum. The maximum tension under
tetanic contraction was registered and normalized to the
sample weight (mg/mg tissue). All data were collected using
a LabChart v7.0 (AD instruments, Spechbach, Germany)
and expressed as mean± S.E.M.
2.11. Statistics. For statistical analysis, IBM SPSS v22.0 (SPSS
Inc.) was used and graphics were drawn with GraphPad
Prism v5.04 (GraphPad Software Inc.). All data were
analyzed by Student’s t-tests, Mann Whitney U test, or
one-way ANOVA with Bonferroni or LSD post hoc
analysis (p < 0 05 was considered signiﬁcant). All presented
data are expressed as means with a corresponding standard
error of the mean (±SEM).
3. Results
3.1. PGC-1α Overexpressing hMPCs Enhance the Levels of
Contractile Muscle Markers during Tissue Regeneration.After
successful isolation, expansion, and characterization of
hMPC from six patient biopsies [14] [28], we evaluated the
eﬀects of PGC-1α overexpressing hMPCs in a TA crush
injury model. To directly assess the role of PGC-1α in
myoﬁber formation, immunoﬂuorescent microscopy and
RTPCR analysis of the regenerating crushed muscle tissue
were performed (Figure 1). The participation of transduced
GFP-positive cells in the myotube formation (α-actinin,
Cy3) over time could be visualized by ﬂuorescent microscopy
in GFP-infected samples (Figure 1(a)) and in PGC-1α-
infected samples (Figure 1(b)). In line with our previous ex
situ results [14], PGC-1α overexpressing-engineered muscle
tissue showed increased relative expression also at gene level
for sarcomeric α-actinin (3.47± 1.45, n = 6, p = 0 5476),
MyHC1 (6440.64± 1370.88, n = 6, p = 0 0238), MyHC2
(7.51± 2.03, n = 6, p = 0 0238), and Desmin (4.78± 1.76,
n = 6, p = 0 0476) at early time points in the regenerating
tissue, relative to GFP samples (Figure 1(c)).
While the Desmin and MyHC2 gene expression reached
equivalent levels in PGC-1α and GFP samples over time
(Figure 1(e); 1.28± 0.29, n = 12, p = 0 5425; 0.55± 0.18,
n = 18, p = 0 0546), the expression of α-actinin and MyHC1
remained signiﬁcantly higher in PGC-1α samples at late
time points (Figure 1(e); 96.15± 24.43, n = 15, p = 0 0092;
312.22± 132.8, n = 18, p = 0 015), suggesting a hPGC-1α-
induced shift towards slow-twitch type ﬁbers.
3.2. Increased Muscle Contraction through PGC-1α
Overexpressing hMPC Injection after Crush Injury. Encour-
aged by the enhanced gene expression of contractile markers
in the regenerating muscles (Figure 1) with increased PGC-
1α levels, we decided to analyze the expression of further
markers, known to be involved in muscle regeneration. The
crushed/regenerating tissue was investigated by RTPCR for
the expression of factors connected to vascularization
(VEGF-A), mitochondrial activity (COXIV), and neuronal
activity (ACHE). The overexpression of hD2R and hPGC-
1α was sustained over time (Figures 2(a)–2(c)). Notably,
the PGC-1α “native” expression in GFP-infected samples
increased at the latest time point (Figure 2(c)). Increased
levels of VEGF-A in hPGC-1α overexpressing samples,
relative to GFP (Figures 2(a)–2(c)), were detected at early
(8–10d) (A: 2.26± 0.49, n = 6, p = 0 0476), midterm (14–
21 d) (B: 7.18± 2.46, n = 21, p = 0 1475), and late (28–35 d)
(C: 204.65± 49.7, n = 18, p = 0 0124) time points. Similarly,
the PGC-1α downstream-regulated mitochondrial activity
was enhanced (COXIV) (A: 4.32± 1.02, n = 6, p = 0 0238; B:
88.87± 38.06, n = 21, p = 0 1475; and C: 1595.35± 547.55,
n = 18, p = 0 003). Finally, the gene expression levels of
ACHE illustrated the expected increase in the PGC-1α-
modiﬁed regenerating tissues (A: 3.96± 1.04, n = 6, p =
0 0238; B: 10.52± 3.51, n = 18, p = 0 0012; and C: 9.99±
2.89, n = 12, p = 0 0032). In line with the enhanced gene
expression of markers for contractility, vascularization,
and neurons, we observed an increased muscle contraction
in hPGC-1α overexpressing muscles. Organ bath measure-
ment at 80V and 80Hz revealed signiﬁcantly elevated con-
traction force at early (PGC-1α: 43.75± 5.27, n = 6; GFP:
28.36± 2.89, n = 13, p = 0 0337) and midterm (PGC-1α:
89.49± 6.14, n = 33; GFP: 69.85± 7.12, n = 18, p = 0 0435)
time points in hPGC-1α-treated muscles (Figure 2(d)). At
late time points, both hPGC-1α and GFP overexpressing
muscles contracted at similar levels (PGC-1α: 82.33± 3.73,
n = 21; GFP: 70.52± 5.17, n = 9, p = 0 0830) as TA native
control. All measurements are relative to contraction of TA
native, which was set as 100%.
3.3. Tracking of hMPC in a TA Muscle Crush Injury by PET/
CT. A crush injury was introduced to the TA muscle of nude
mice (Figure 3(a)). The injected hD2R_hMPCs were success-
fully tracked in the crush injury region using the speciﬁc D2R
radiotracer [18F]Fallypride (early time point), resulting in a
virus dose-dependent signal (Figure 3(b)). The injection of
50% hD2R-positive cells in the damaged tissue led to an
increased radiotracer uptake, compared to the injection of
25% positive cells. No signal could be detected in the crush
only controls. To exclude signal contamination from 18F-
ﬂuoride in the tibial bone, [11C]Raclopride was used as an
alternative high-aﬃnity D2R ligand for further experiments.
For these experiments, a viral combination of hD2R and
hPGC-1α, compared to GFP control infected cells, was used
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(Figures 3(c) and 3(d)). Uptake of [11C]Raclopride could be
detected in hD2R_hPGC-1α_hMPCs at early time points only
(Figure 3(c)). Further analysis indicated an unspeciﬁc radio-
tracer uptake at the site of injury also whenGFP_hMPCs were
used (Figure 3(d)). Importantly, the accumulation of the
radiotracer in the intestines, urinary bladder, and joints
(18F–ﬂuoride) is a known PK (pharmacokinetic) property of
the radiotracer and should be considered physiologic and
nonspeciﬁc accumulation for the current application.
3.4. PGC-1α Overexpressing hMPCs Reduce the
Proinﬂammatory Response after Muscle Crush Injury. Ini-
tially aiming at imaging of neoangiogenesis with the speciﬁc
αvßIII radiotracer [
64Cu]NODAGA-RGD, we observed a
highly increased accumulation of the tracer in TA crush only
in the early periods after injury, when compared to native
TA and to the crushed muscles with injected hMPCs
(Figure 4(a), early). At later time points, no PET signal
was detectable (Figure 4(a), midterm and late). Furthermore,
immunohistological analysis of harvested muscles with a
macrophage expression marker (F4/80, Cy3) demonstrated
(1) a highly increased macrophage accumulation in crushed
TA compared to native (Figures 4(b) and 4(c), early) and
(2) a decreased signal in the hD2R_hPGC_hMPCs compared
to GFP_hMPCs (Figures 4(b) and 4(c), early). The latter
eﬀect was observed also at later time points (Figures 4(b)
and 4(c), midterm and late). RTPCR analysis of the proin-
ﬂammatory cytokine TNF-α in the crushed/regenerating tis-
sue conﬁrmed the highly increased signal in TA crush versus
TA native (Figure 4(d), early, 44.73± 4.52, n = 3, 0.57± 0.19,
n = 6, p < 0 0001) and the decreased expression in PGC-1α
overexpressing tissues compared to GFP (Figure 4(d), early,
0.443± 0.11, n = 3, 0.98± 0.07, n = 3, p = 0 0177). The PGC-
1α-related reduction of inﬂammation was sustained also at
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Figure 1: PGC-1α induces upregulation of the expression of contractile genes in regenerating muscle. Immunohistological assessment of
newly built muscle ﬁbers (green), stained with sarcomeric α-actinin antibody (Cy3, red) over time ((a) GFP and (b) PGC-1α). RTPCR
analysis showed enhanced α-actinin, MyHC1, MyHC2, and Desmin gene expression when PGC-1α was overexpressed at (c) early
(9± 1 d), (d) midterm (18± 3 d), and (e) late (31± 3 d) time points after the TA crush injury. TAcr: tibialis anterior crushed. ∗p < 0 05
and ∗∗p < 0 01.
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midterm (Figure 4(d), 0.23± 0.03, n = 15, 1.35± 0.30, n = 3,
p < 0 0001) and late time points (Figure 4(d), 0.15± 0.02,
n = 9, 0.84± 0.24, n = 3, p = 0 0005).
4. Discussion
Autologous stem cell therapy is on the doorstep to successful
clinical application and represents a novel treatment option
for various muscle-related pathologies, including urinary
and anal incontinence, vocal cord dysfunction, and reﬂux.
Muscle precursor cells, or activated satellite cells, are respon-
sible for the regeneration in postnatal skeletal muscles. In the
past decades, these cells have been investigated for muscle
tissue bioengineering approaches, allowing the growth of
new myoﬁbers [2, 3, 32, 33]. However, there are certain
limitations in the quality of the de novo engineered con-
structs. The process of proliferation and diﬀerentiation of
these cells is largely driven by growth factors and altered by
tissue injury or exercise [34, 35]. To address this matter, we
designed a model for facilitated muscle regeneration after
injury, by inducing overexpression of hPGC-1α in the
injected hMPCs in the injured skeletal muscles.
Intensive research has shown that the natural process
after muscle injury follows a highly conserved sequence of
steps, leading to the restoration of tissue architecture, and
importantly also function [36]. A crucial step in the process
of forming new muscle tissue is the capacity of MPCs to
diﬀerentiate into myotubes. Consistent with the previously
reported facilitated in vitro and in vivo ex situ diﬀerentiation
of hPGC-1α_hMPCs [14], the regenerating TA muscles with
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Figure 2: PGC-1α_hMPCs induce expression of genes related to vascularization, mitochondrial, and neuronal activation and enhance the
contractility at early and midterm time points after TA crush injury during regeneration. RTPCR analysis conﬁrmed the sustained
overexpression of hPGC-1α and the signalling-deﬁcient hD2R genes at the crush injury site over time. Relative VEGF-A, COXIV, and
ACHE gene levels were enhanced in the corresponding samples, compared to control GFP_hMPC at (a) early, (b) midterm, and (c) late
time points of regeneration. (d) PGC-1α overexpression led to increased TA contractile force at early and midterm time points.
Native TA muscle (TA nat) was used as control, and the contraction force was set to 100%. Forces of injured muscles were
calculated relatively as the percentage of maximum. VEGF-A: vascular endothelial growth factor-a, COXIV: cytochrome c oxidase subunit
4, ACHE: acetylcholine esterase. ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001.
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hPGC-1α overexpression demonstrated earlier myotube
formation in situ. This would facilitate the functional regen-
eration in patients with a damaged urinary sphincter. The
injection of hPGC-1α_hMPC in the crush injury also signif-
icantly increased the expression of contractile proteins at all
time points after the injury, indicating facilitated restoration
compared to GFP-infected controls. Importantly, the expres-
sion of MyHC1 was signiﬁcantly increased in the hPGC-
1α_hMPC samples, correlating with our goal to bioengineer
predominantly slow-twitch muscle ﬁbres, such as in the
external urinary sphincter [12]. In line with our in vivo obser-
vations, others have shown that an increased VEGF release in
a hypoxic environment leads to enhanced diﬀerentiation of
muscle cells [37]. It has been demonstrated that secretion of
various eﬀectors by injected hMPCs contribute to optimiza-
tion of the regenerative process (e.g., neovascularization)
[32, 38, 39]. The hPGC-1α-related regeneration enhance-
ment was further promoted by an increase in factors for
mitochondrial (COXIV) and neuromuscular (ACHE) activ-
ity, which are known to be vital for successful muscle tissue
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Figure 3: PET/CT tracking of hD2R_hMPCs in a TA crush injury model. (a) Nude mice were subjected to a TA crush injury, followed
by injection of cell collagen suspension. (b) Feasible tracking of hD2R_hMPCs with [18F]Fallypride in a virus dose-dependent manner
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bioengineering. Further supporting evidence suggested an
increased expression of mitochondrial and other metabolic
genes as a plausible mechanism for rescuing a damaged mus-
cle [18]. All these factors support the observed facilitated
contraction force production by the regenerating muscles
injected with hPCG-1α_hMPC. At the later time points,
there was no signiﬁcant diﬀerence between the contraction
forces of the two groups. This was expected, as the regenera-
tion of the muscles at later stages was completed, and there
was no diﬀerence to native TA contraction. Although the
functional results (organ bath) suggest a diminished diﬀer-
ence between the two groups in long-term, the data support
our main aim for designing a model for signiﬁcantly
facilitated muscle regeneration. One has to consider certain
limitations of the approach; for example, the use of
young mice brings along fast self-regeneration that might
not be the best comparison model to the real situation in
elderly patients. Nevertheless, we could show signiﬁcant
improvement of the regeneration speed even in a highly
self-regenerative environment. We expect to observe an even
more prominent eﬀect on facilitated muscle regeneration in
patients. Moreover, GFP_hMPC-injected muscles showed
increased PGC-1α gene expression levels at the latest stages,
comparable to these in hPGC-1a_hMPC samples.
While resistance training combined with adequate nutri-
tion remains the most eﬀective intervention to diminish the
functional decline in muscles, there is a certain age-linked
barrier to obtaining full beneﬁts from this therapy [40].
PGC-1α would be a promising “exercise molecule,” which
controls skeletal muscle metabolism and has potential thera-
peutic eﬀects. Therefore, we believe that by inducing hPGC-
1α overexpression in the injected hMPCs, we are able to
mediate muscle-healing eﬀects for structural, metabolic,
and functional restoration, irrespective of physical status
and age of the patient. This makes the current preclinical
approach a good candidate for regenerating the urinary
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Figure 4: PGC-1α overexpression in hMPCs reduces the inﬂammatory response in the crush injury. (a) Unspeciﬁc accumulation of
neovascularization radiotracer [64Cu]NODAGA-RGD in the early time points after the injury. (b) Immunohistological assessment of
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sphincter in patients suﬀering from stress urinary inconti-
nence in near future.
Besides improving the quality of the engineered skeletal
tissues, we aimed at establishing a method to noninvasively
image the cell fate after implantation, circumventing the need
for a tissue biopsy. Molecular imaging with PET is gaining
increasing importance in regenerative medicine due to the
possibility for noninvasive metabolic read-outs. A recent
study described the feasibility of imaging human Na/I sym-
porter (NIS) expression in two mouse models of muscular
dystrophy and vascular disease by bioluminescence and
PET imaging [41]. This study demonstrated that luciferase-
and NIS-engineered skeletal muscle could successfully be
imaged. In our present study, we presented a method for
noninvasive visualization of the implanted cells in the TA
crush injury using PET/CT imaging of hD2R. Tracking of
hMPCs via ectopic expression of a signalling-deﬁcient
hD2R was previously reported in an ex situ muscle tissue for-
mation model [28]. We were able to visualize the cells in a
viral dose-dependent manner in the injured TA muscles of
the animals using the highly-speciﬁc hD2R radiotracer
[18F]Fallypride. Nevertheless, the proximity of the muscle
injury to the tibial bone led to unspeciﬁc signal uptake due
to possible deﬂuorination of the radiotracer. To circumvent
this problem, we used [11C]Raclopride as an alternative
hD2R PET imaging agent.
Interestingly, animals injected with GFP-only hMPCs
showed higher [11C]Raclopride uptake, compared to the
regenerating muscles with injected hD2R_hPGC-1α_
hMPCs. This was also true for other tracers investigated in
the study (e.g., [18F]FDG, data not shown). Additionally,
while aiming at visualizing neovascularization using
[64Cu]NODAGA-RGD, a relatively high amount of radioac-
tivity was detected in the TA crushed only, where no cells
were injected. These observations led to the assumption that
the recorded signals were rather related to inﬂammation,
than to vascularization or speciﬁc hD2R detection. Immuno-
histological analysis with the macrophage marker F4/80 and
the TNF-α gene expression levels in the harvested samples
correlated with [64Cu]NODAGA-RGD tracer uptake in the
injury region. In line with our observations, another study
revealed that in addition to neovessels and myoﬁbroblasts,
macrophages have also been shown to express αvβIII integrin
[42]. However, the relative amounts of integrin in these cell
types have not been followed over time. Importantly, we were
able to show that hPGC-1α overexpression in the hMPCs
could signiﬁcantly reduce proinﬂammatory cytokine expres-
sion (TNF-α) and enhance the healing process. A relation
between hPGC-1α and suppression of the broad inﬂamma-
tory response has previously been reported [18].
5. Conclusions
Based on the ﬁndings above, hPGC-1α overexpressing
hMPCs hold a promise for the enhanced repair of skeletal
muscle tissue. They demonstrated capacities to amplify the
expression of contractile markers, to facilitate the contraction
force generation in the regenerating muscles, and to decrease
the inﬂammatory response after crush injury. Additionally,
we were able to track the implanted cells in the crushed
muscles using PET radioligands. Nonetheless, several chal-
lenges remain which need to be overcome in order to
establish a feasible method for metabolic imaging of this
cellular therapy.
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